Trial Profile
Phase Ib/IIa Study of Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 16 Jan 2023
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Lenalidomide (Primary) ; Romidepsin (Primary)
- Indications B-cell lymphoma; T-cell lymphoma
- Focus Adverse reactions
- 11 Jan 2023 Status changed from active, no longer recruiting to completed.
- 01 Feb 2022 Planned End Date changed from 1 Jan 2022 to 1 Jan 2023.
- 01 Feb 2022 Planned primary completion date changed from 1 Jan 2022 to 1 Jan 2023.